News
August 23, 2022

Regenstrief research scientist to lead American Delirium Society for 2023-24 term 

Regenstrief Research Scientist Noll Campbell, PharmD, M.S., has been voted president-elect of the American Delirium Society (ADS) by the board of directors. Dr. Campbell will be installed into office in conjunction with the society’s national conference in June of 2023.

Delirium is a sudden change in brain function leading to confusion and reduced awareness of a person’s surroundings. People in the intensive care unit often experience delirium.

Dr. Campbell’s research is focused on the recognition and measurement of adverse cognitive effects of medications in older adults with acute and chronic cognitive impairment, including delirium and dementia. This work includes the identification and implementation of tools and processes to mitigate the adverse cognitive effects of medications.

“Delirium is a sign of acute brain dysfunction and more common in older adults. It has also been repeatedly associated with long-term cognitive impairment and dementia,” said Dr. Campbell. “It complicates recovery from acute illness, and costs victims, their families and healthcare systems vast amounts of resources. Reducing these costs and complications of delirium would significantly improve the outlook of the aging population.”

Dr. Campbell maintains an active clinical practice as a geriatric pharmacotherapy expert within Eskenazi Health, supporting the translation and implementation of his research into clinical care.

“I’m excited and gratified to be a part of this society and lead the charge toward eradicating delirium through continued research and collaboration with national and international partners committed to improving delirium science,” said Dr. Campbell.

In his role as the society’s president, Dr. Campbell will oversee the society’s programs and guide resources to advance the mission of advocacy for patients and dissemination of research and best practices.

Regenstrief Research Scientist Malaz Boustani, M.D., MPH, was the founding president of ADS. Babar Khan, M.D., M.S., another Regenstrief research scientist, served as the 2019-2020 president. Both Drs. Campbell and Khan are current members of the ADS board of directors.

The mission of ADS is to encourage research, education, quality improvement, advocacy and implementation science to diminish the influence of delirium on short- and long-term health and welfare of patients.

Noll Campbell, PharmD, M.S.
In addition to his role as a research scientist at Regenstrief Institute, Noll Campbell, PharmD, M.S., is an adjunct associate professor of medicine at Indiana University School of Medicine and an associate professor of pharmacy practice at the Purdue University College of Pharmacy.

About Regenstrief Institute
Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute’s research mission.

About American Delirium Society
An initiative to foster collaboration among medical centers, an interdisciplinary group of professionals began holding monthly conference calls in 2005. As the number of interested centers increased, so did the activity of the group – starting with an editorial in a medical journal leading to a development of a national conference symposium and finally the American Delirium Society. These professionals believed strongly that delirium is a threat to the health and independence of older patients. Based on this belief, the group enlisted the help of professionals in all specialties from across America to organize in our quest to better understand the science of delirium and its prevention, treatment, and long-term consequences. Thus, was born the American Delirium Society.

Related News

image of pregnant woman with vaccine acting as protection from COVID virus

National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy

The first large, real-world study of the effectiveness of mRNA COVID-19 vaccines during pregnancy found these vaccines, especially two

Thomas Imperiale

Journal editorial: Regenstrief researcher calls for tailoring colorectal cancer screening for 45-to-49-year-olds

It’s been a year since national recommendations issued by the American Cancer Society and the U.S. Multi-Society Task Force

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Regenstrief Vice President for Data and Analytics Shaun Grannis, M.D., M.S., discusses the questions that will be investigated in

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Widely used scales measure pain, depression, anxiety, suicide risk, cancer fatigue and now symptoms associated with a common dental